Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BMS-986326 in Healthy Participants
NCT04736134Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986326 in systemic lupus erythematosus (SLE), atopic dermatitis (AD) and autoimmune diseases (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events (AEs) up to 175 days, Number of participants with clinical laboratory abnormalities up to 175 days and 2 more. Started Mar 2021; status: completed.
02
Drugs
BMS-986326
03
Conditions
systemic lupus erythematosus (SLE)atopic dermatitis (AD)autoimmune diseases
Beyond the preview
Go deeper on NCT04736134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736134.